

医药制造业务的历史





在过去的几十年里，印度制药业在全球崭露头角，成为全球最大的非专利药品生产国之一。印度制药业的业务呈指数级增长，在国内和国际市场上的影响力不断扩大。

印度制药业拥有庞大的专业技术人才库、成本效益高的制造能力和大规模生产能力，因此潜力巨大。该国强大的研发基础设施进一步促进了其制药业务的成功。

印度拥有多家知名的制药研究机构，并有健全的监管框架来确保达到质量标准。

近年来，印度制药业取得了重大成就。

该公司成功开发和生产了多种非专利药品，从而使全球范围内的医疗保健服务更加经济实惠，更容易获得。

印度药品的可负担性在为发展中国家提供医疗解决方案方面发挥了至关重要的作用，同时也为降低发达国家的医疗成本做出了贡献。

印度在生产高质量非专利药品方面的专长也使其成为世界各国药品的主要供应国。

印度制药公司通过在不同国家建立生产设施和研究中心来扩大业务，从而满足不同市场的特殊需求。

印度的制药企业不仅专注于仿制药，在药品研发方面也取得了长足进步。

一些印度公司在创新药物研发方面进行了大量投资，重点关注生物技术和生物仿制药。

因此，印度开发出了治疗各种疾病的突破性药物，提高了印度作为制药创新中心的声誉。

概述

总部位于印度的跨国制药公司。它是亚洲领先的非专利制药公司之一，在 30 多个国家开展业务，拥有从处方药到非处方药和活性药物成分的多样化产品组合。

该公司以其强大的研发能力而闻名，并以生产质优价廉的药品而著称。

公司致力于在全球范围内改善医疗服务的可及性，并努力通过创新产品和可持续发展实践对人们的生活产生积极影响。

目前，公司主要经营自有品牌，不对自有品牌进行商业化，但生产大多数常见的药品剂型（糖浆、胶囊、片剂、粉剂、乳剂、溶液剂）。

要点

1. 专注于生产和销售非专利药品、活性药物成分 (API) 以及定制制药服务。

TARGET PRICE

\$1,050,000,000

GROSS REVENUE

\$306,500,000

EBITDA

\$87,500,000

BUSINESS TYPE

制药

COMPETITION

Lupin Limited, Cadila
Healthcare, Torrent
Pharmaceuticals, Aurobindo,
Pharma, Biocon, Glenmark
Pharmaceuticals, Alkem
Laboratories

SUPPORT & TRAINING

24个月

REASON FOR SELLING

剥离

COUNTRY

印度

BUSINESS ID

L#20240605

2. 公司拥有多样化的产品组合，涵盖心血管、神经、胃肠、皮肤和肿瘤等多个治疗类别。
3. 业务遍及全球 30 多个国家。
4. 高度重视研发工作，将收入的很大一部分用于研发活动。
5. 由科学家和研究人员组成的专业团队，致力于开发新型药物制剂和改进现有药物制剂。
6. 新产品储备充足，已在多个国家申请并获得批准。
7. 以重视质量和遵守国际监管标准而著称。
8. 在印度和国外拥有多家制造工厂，均遵守良好生产规范 (GMP) 指南。
9. 在全球范围内成功推出和营销非专利版大片药物的良好记录。
10. 与领先的制药公司建立伙伴关系和合作关系，以获得新的分子和市场。

需要 KYC、POF

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM